<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28206704</article-id><article-id pub-id-type="pmc">5485164</article-id><article-id pub-id-type="doi">10.1111/dom.12909</article-id><article-id pub-id-type="publisher-id">DOM12909</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Lipid&#x02010;lowering efficacy and safety of alirocumab in patients with or without diabetes: <styled-content style="fixed-case">A</styled-content> sub&#x02010;analysis of <styled-content style="fixed-case">ODYSSEY COMBO II</styled-content>
</article-title><alt-title alt-title-type="right-running-head"><styled-content style="fixed-case">LEITER</styled-content> et al.</alt-title><alt-title alt-title-type="left-running-head"><styled-content style="fixed-case">LEITER</styled-content> et al.</alt-title></title-group><contrib-group><contrib id="dom12909-cr-0001" contrib-type="author" corresp="yes"><name><surname>Leiter</surname><given-names>Lawrence A.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1040-6229</contrib-id><address><email>leiterl@smh.ca</email></address><xref ref-type="aff" rid="dom12909-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12909-cr-0002" contrib-type="author"><name><surname>Zamorano</surname><given-names>Jos&#x000e9; Luis</given-names></name><xref ref-type="aff" rid="dom12909-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12909-cr-0003" contrib-type="author"><name><surname>Bujas&#x02010;Bobanovic</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="dom12909-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12909-cr-0004" contrib-type="author"><name><surname>Louie</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="dom12909-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12909-cr-0005" contrib-type="author"><name><surname>Lecorps</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="dom12909-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12909-cr-0006" contrib-type="author"><name><surname>Cannon</surname><given-names>Christopher P.</given-names></name><xref ref-type="aff" rid="dom12909-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12909-cr-0007" contrib-type="author"><name><surname>Handelsman</surname><given-names>Yehuda</given-names></name><xref ref-type="aff" rid="dom12909-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="dom12909-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Li Ka Shing Knowledge Institute and Keenan Research Center for Biomedical Science</named-content><institution>St. Michael's Hospital, University of Toronto</institution><named-content content-type="city">Toronto</named-content><country country="CA">Canada</country></aff><aff id="dom12909-aff-0002"><label><sup>2</sup></label><institution>Hospital Universitario Ramon y Cajal, University Alcala de Henares</institution><named-content content-type="city">Madrid</named-content><country country="ES">Spain</country></aff><aff id="dom12909-aff-0003"><label><sup>3</sup></label><institution>Sanofi</institution><named-content content-type="city">Paris</named-content><country country="FR">France</country></aff><aff id="dom12909-aff-0004"><label><sup>4</sup></label><institution>Regeneron Pharmaceuticals</institution><named-content content-type="city">Tarrytown</named-content><named-content content-type="country-part">New York</named-content></aff><aff id="dom12909-aff-0005"><label><sup>5</sup></label><institution>Brigham and Women's Hospital</institution><named-content content-type="city">Boston</named-content><named-content content-type="country-part">Massachusetts</named-content></aff><aff id="dom12909-aff-0006"><label><sup>6</sup></label><institution>Metabolic Institute of America</institution><named-content content-type="city">Tarzana</named-content><named-content content-type="country-part">California</named-content></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Dr Lawrence A. Leiter, Division of Endocrinology and Metabolism, University of Toronto, St. Michael's Hospital, 61 Queen Street East, #6121, Toronto, Ontario M5C 2T2, Canada. Email: <email>leiterl@smh.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><volume>19</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-7</issue-id><fpage>989</fpage><lpage>996</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-989.pdf"/><abstract id="dom12909-abs-0001"><sec id="dom12909-sec-0001"><title>Aim</title><p id="dom12909-para-0004">This sub&#x02010;analysis of the <styled-content style="fixed-case">ODYSSEY COMBO II</styled-content> study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (<styled-content style="fixed-case">PCSK9</styled-content>) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) receiving maximally tolerated statin therapy.</p></sec><sec id="dom12909-sec-0002"><title>Methods</title><p id="dom12909-para-0005">
<styled-content style="fixed-case">COMBO II</styled-content> was a 104&#x02010;week, double&#x02010;blind study (n&#x02009;=&#x02009;720) enrolling patients with documented atherosclerotic cardiovascular disease (<styled-content style="fixed-case">ASCVD</styled-content>) and baseline <styled-content style="fixed-case">LDL&#x02010;C</styled-content> &#x02265;70&#x02009;mg/dL (1.8&#x02009;mmol/L), and patients without documented <styled-content style="fixed-case">ASCVD</styled-content> at high cardiovascular risk with <styled-content style="fixed-case">LDL&#x02010;C</styled-content> &#x02265;100&#x02009;mg/dL (2.6&#x02009;mmol/L). Patients receiving maximally tolerated statin therapy were randomized (2:1) to alirocumab 75&#x02009;mg every 2&#x02009;weeks (<styled-content style="fixed-case">Q2W</styled-content>; 1&#x02009;mL subcutaneous injection) or oral ezetimibe 10&#x02009;mg daily. Alirocumab dose was increased to 150&#x02009;mg <styled-content style="fixed-case">Q2W</styled-content> (also 1&#x02009;mL) at <styled-content style="fixed-case">W</styled-content>eek 12 if <styled-content style="fixed-case">W</styled-content>eek 8 <styled-content style="fixed-case">LDL&#x02010;C</styled-content> was &#x02265;70&#x02009;mg/dL.</p></sec><sec id="dom12909-sec-0003"><title>Results</title><p id="dom12909-para-0006">History of <styled-content style="fixed-case">DM</styled-content> was reported in 31% (n&#x02009;=&#x02009;148) of patients on alirocumab and 32% (n&#x02009;=&#x02009;77) of patients on ezetimibe. At <styled-content style="fixed-case">W</styled-content>eek 24, alirocumab consistently reduced <styled-content style="fixed-case">LDL&#x02010;C</styled-content> from baseline in patients with (&#x02212;49.1%) or without <styled-content style="fixed-case">DM</styled-content> (&#x02212;51.2%) to a significantly greater extent than ezetimibe (&#x02212;18.4% and &#x02212;21.8%, respectively). Occurrence of treatment&#x02010;emergent adverse events was similar between groups. Efficacy results at 104&#x02009;weeks were similar to those at 24&#x02009;weeks.</p></sec><sec id="dom12909-sec-0004"><title>Conclusions</title><p id="dom12909-para-0007">Over a 104&#x02010;week double&#x02010;blind study period, alirocumab provided consistently greater <styled-content style="fixed-case">LDL&#x02010;C</styled-content> reductions than ezetimibe, with similar <styled-content style="fixed-case">LDL&#x02010;C</styled-content> results in patients with or without <styled-content style="fixed-case">DM</styled-content>. Safety of alirocumab was similar regardless of baseline <styled-content style="fixed-case">DM</styled-content> status.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12909-kwd-0001">cardiovascular disease</kwd><kwd id="dom12909-kwd-0002">clinical trial</kwd><kwd id="dom12909-kwd-0003">dyslipidaemia</kwd><kwd id="dom12909-kwd-0004">type 1 diabetes</kwd><kwd id="dom12909-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Sanofi and Regeneron Pharmaceuticals</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="1"/><word-count count="5145"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12909</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12909-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.2 mode:remove_FC converted:27.06.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12909-cit-0000">
<string-name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Zamorano</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Bujas&#x02010;Bobanovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Louie</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lecorps</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name> and <string-name>
<surname>Handelsman</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Lipid&#x02010;lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub&#x02010;analysis of ODYSSEY COMBO II</article-title>, <source>Diabetes Obes Metab</source>, <year>2017</year>;<volume>19</volume>:<fpage>989</fpage>&#x02013;<lpage>996</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12909">https://doi.org/10.1111/dom.12909</ext-link>
<pub-id pub-id-type="pmid">28206704</pub-id></mixed-citation>
</p></notes><notes><fn-group id="dom12909-ntgp-0001"><fn id="dom12909-note-0001"><p>
<bold>Funding Information</bold> The ODYSSEY COMBO II study was supported by Sanofi and Regeneron Pharmaceuticals. The authors were responsible for all content and editorial decisions and received no honoraria related to the development/presentation of this publication.</p></fn></fn-group></notes></front><body><sec id="dom12909-sec-0005"><label>1</label><title>INTRODUCTION</title><p id="dom12909-para-0008">Diabetes mellitus (DM) is associated with an atherogenic lipid profile, typically characterized by elevated levels of plasma triglycerides (TGs) and reduced concentrations of high&#x02010;density cholesterol (HDL&#x02010;C).<xref rid="dom12909-bib-0001" ref-type="ref">1</xref> Individuals with diabetes mellitus (DM) are considered to be at high risk of atherosclerotic cardiovascular disease (ASCVD), and guidelines recommend that such patients receive lipid&#x02010;lowering treatment to reduce levels of low&#x02010;density lipoprotein cholesterol (LDL&#x02010;C).<xref rid="dom12909-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12909-bib-0003" ref-type="ref">3</xref>, <xref rid="dom12909-bib-0004" ref-type="ref">4</xref> In addition, levels of non&#x02010;high&#x02010;density lipoprotein cholesterol (non&#x02010;HDL&#x02010;C) more closely align with cardiovascular risk in individuals with DM, and reducing non&#x02010;HDL&#x02010;C has been recommended as an alternative treatment target.<xref rid="dom12909-bib-0005" ref-type="ref">5</xref> However, a high percentage of patients with DM fail to achieve adequate control of LDL&#x02010;C or non&#x02010;HDL&#x02010;C levels with existing lipid&#x02010;lowering therapies and therefore remain at high risk of ASCVD.</p><p id="dom12909-para-0009">Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). In the ODYSSEY Phase 3 clinical trial program, comprising a comprehensive evaluation of alirocumab in patients with dyslipidaemia and increased ASCVD risk (including 31.0% with DM, n&#x02009;=&#x02009;223), alirocumab was associated with average reductions in LDL&#x02010;C of 49% with alirocumab 75&#x02009;mg/150&#x02009;mg every 2&#x02009;weeks (Q2W; 75&#x02009;mg/150&#x02009;mg denotes that the initial dose of 75&#x02009;mg Q2W was increased to 150&#x02009;mg Q2W at Week 12 depending on Week 8 LDL&#x02010;C), and 61% with alirocumab 150&#x02009;mg Q2W.<xref rid="dom12909-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12909-bib-0007" ref-type="ref">7</xref> In the 104&#x02010;week, Phase 3 ODYSSEY COMBO II trial (n&#x02009;=&#x02009;720), as previously reported, alirocumab 75&#x02009;mg/150&#x02009;mg Q2W significantly reduced LDL&#x02010;C vs ezetimibe in high risk cardiovascular patients receiving background maximally tolerated statin. Mean&#x02009;&#x000b1;&#x02009;SE reductions in LDL&#x02010;C from baseline at Week 24 were 50.6%&#x02009;&#x000b1;&#x02009;1.4% for alirocumab vs 20.7%&#x02009;&#x000b1;&#x02009;1.9% for ezetimibe (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001).<xref rid="dom12909-bib-0008" ref-type="ref">8</xref> Approximately one third of patients in COMBO II had DM at baseline (n&#x02009;=&#x02009;225) and 24&#x02010;week data revealed similar reductions in LDL&#x02010;C in patients with or without DM.<xref rid="dom12909-bib-0008" ref-type="ref">8</xref> The purpose of this sub&#x02010;analysis was to investigate in greater detail whether the efficacy and safety of alirocumab, administered to patients receiving maximally tolerated statin, differs between those with DM and those without DM over the long term, using data from the COMBO II study.</p></sec><sec id="dom12909-sec-0006"><label>2</label><title>METHODS</title><p id="dom12909-para-0010">The double&#x02010;blind COMBO II study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> identifier: NCT01644188) enrolled patients with documented ASCVD and baseline LDL&#x02010;C &#x02265;70&#x02009;mg/dL (1.8&#x02009;mmol/L) and patients without documented ASCVD but with other risk factors and LDL&#x02010;C &#x02265;100&#x02009;mg/dL (2.6&#x02009;mmol/L). All patients in the study were defined as being at high cardiovascular risk. ASCVD was defined as the presence of coronary heart disease (CHD), peripheral artery disease (PAD) or ischaemic stroke. Other risk factors included moderate chronic kidney disease (estimated glomerular filtration rate (eGFR) &#x0003c;60mL/min/1.73 m<sup>2</sup>, for 3&#x02009;months or more, including screening; note that patients with eGFR &#x0003c;30&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> were excluded from the study) and known history of diabetes in addition to &#x02265;2 additional related risk factors (including hypertension, ankle&#x02010;brachial index &#x02264;0.90, microalbuminuria or macroalbuminuria or dipstick urinalysis at screening with &#x0003e;2+ protein, history of pre&#x02010;proliferative or proliferative retinopathy, family history of premature CHD). Trial methods have been published in detail elsewhere.<xref rid="dom12909-bib-0009" ref-type="ref">9</xref> The study was performed in accordance with principles of the Declaration of Helsinki and all applicable amendments by the World Medical Assemblies and the International Conference on Harmonization Guidelines for Good Clinical Practice. The protocol was approved by the institutional review boards of participating centres. All participants gave written informed consent.</p><sec id="dom12909-sec-0007"><label>2.1</label><title>Patients</title><p id="dom12909-para-0011">Patients were randomized (2:1) to subcutaneous (SC) alirocumab 75&#x02009;mg Q2W or oral ezetimibe 10&#x02009;mg/d. At Week 12, the alirocumab dose was increased to 150&#x02009;mg Q2W if Week 8 LDL&#x02010;C was &#x02265;70&#x02009;mg/dL (1.8&#x02009;mmol/L) (Figure <xref rid="dom12909-supitem-0001" ref-type="supplementary-material">S1</xref>). DM at baseline was considered present if a Custom Medical Dictionary for Regulatory Activities (MedDRA) Query (CMQ) of the medical history reported &#x0201c;diabetes.&#x0201d;
</p><p id="dom12909-para-0012">All patients were receiving concomitant maximally tolerated statin therapy (defined as atorvastatin 40&#x02010;80&#x02009;mg, rosuvastatin 20&#x02010;40&#x02009;mg, or simvastatin 80&#x02009;mg), unless an investigator&#x02010;approved reason was given, for example, intolerance to high doses. Other background non&#x02010;statin lipid&#x02010;lowering therapies were not allowed. Patients were instructed to remain on a National Cholesterol Education Program Adult Treatment Panel III therapeutic lifestyle changes diet or equivalent and to maintain the same daily dose of statin throughout the study.<xref rid="dom12909-bib-0009" ref-type="ref">9</xref>
</p></sec><sec id="dom12909-sec-0008"><label>2.2</label><title>Endpoints</title><p id="dom12909-para-0013">The present analysis compared alirocumab efficacy and safety in high risk cardiovascular patients with or without DM over a period of 104&#x02009;weeks,<xref rid="dom12909-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12909-bib-0009" ref-type="ref">9</xref> and was a sub&#x02010;analysis of the COMBO II study. The primary efficacy endpoint was pre&#x02010;specified, while the secondary endpoints and safety assessments were post&#x02010;hoc analyses. The primary efficacy endpoint was the percent change in calculated LDL&#x02010;C from baseline to Week 24, analysed using an intent&#x02010;to&#x02010;treat (ITT) approach including all lipid data, whether patients were on or off treatment. An on&#x02010;treatment analysis using lipid data collected during the treatment period was also conducted with all patients who received at least 1 dose or part of a dose of the double&#x02010;blind study injection and had an evaluable primary efficacy endpoint during the efficacy treatment period. <italic>S</italic>econdary endpoints included percent change from baseline in LDL&#x02010;C at Week 12 (before potential alirocumab dose increase); achievement of risk&#x02010;based LDL&#x02010;C goals at Week 24; percent changes from baseline in HDL&#x02010;C, TGs, non&#x02010;HDL&#x02010;C, apolipoprotein (Apo) B, Apo A1 and lipoprotein (a) [Lp(a)] at Week 24. Percent changes in all lipids are also presented up to Week 104, using both ITT and on&#x02010;treatment approaches. Safety was assessed through analysis of adverse event (AE) reports and laboratory analyses (including mean change in fasting glucose [FG] and glycated haemoglobin [HbA1c] at Week 24) from the time of signed informed consent until end of study, with a 70&#x02010;day follow&#x02010;up period.</p></sec><sec id="dom12909-sec-0009"><label>2.3</label><title>Statistical analyses</title><p id="dom12909-para-0014">Efficacy endpoints were analysed using a mixed effect model with a repeated measures approach to account for missing data for all lipid parameters, except Lp(a) and TGs and achievement of LDL&#x02010;C goals, which were analysed using a multiple imputation approach for handling of missing values, followed by robust regression, and achievement of LDL&#x02010;C goals, which was analysed using a multiple imputation approach for handling of missing values, followed by logistic regression. The significance level of the treatment&#x02010;by&#x02010;DM subgroup factor interaction term at Week 24 was also derived from the mixed effect model with repeated measures. Safety data were analysed using descriptive statistics. Analyses were performed using SAS version 9.2 software (SAS Institute Inc., Cary, North Carolina).</p></sec></sec><sec id="dom12909-sec-0010"><label>3</label><title>RESULTS</title><p id="dom12909-para-0015">Overall, 720 patients were randomized, including 225 (31%) patients with DM and 495 (69%) without DM. DM patients were evenly distributed in the alirocumab (n&#x02009;=&#x02009;148; 31%) and ezetimibe arms (n&#x02009;=&#x02009;77; 32%). Across the treatment and DM subgroups, the mean age was 60.4 to 63.2&#x02009;years and mean body mass index ranged from 29.2 to 32.5&#x02009;kg/m<sup>2</sup> (Table <xref rid="dom12909-tbl-0001" ref-type="table-wrap">1</xref>). Baseline levels of lipids, including LDL&#x02010;C, non&#x02010;HDL&#x02010;C, apo B, Lp(a) and HDL&#x02010;C, were similar between the alirocumab and ezetimibe groups within the DM and non&#x02010;DM subgroups (Table <xref rid="dom12909-tbl-0001" ref-type="table-wrap">1</xref>). Mean baseline HbA1c was 6.8% in patients with DM and 5.7% in patients without DM. Mean baseline FG was 134.1&#x02009;mg/dL (7.44&#x02009;mmol/L; alirocumab) and 132.0&#x02009;mg/dL (7.33&#x02009;mmol/L; ezetimibe) in DM subgroups and 104.0&#x02009;mg/dL (5.77&#x02009;mmol/L; alirocumab) and 103.6&#x02009;mg/dL (5.75&#x02009;mmol/L; ezetimibe) in non&#x02010;DM subgroups (Table <xref rid="dom12909-tbl-0001" ref-type="table-wrap">1</xref>). For the DM cohort, the mean duration of DM was 9.5&#x02009;years in both treatment arms. Furthermore, 85.1% and 81.8% of patients with DM were receiving at least 1 glucose&#x02010;lowering agent at randomization in the alirocumab and ezetimibe groups, respectively. In total, 22.3% in the alirocumab group and 16.9% in the ezetimibe group were receiving insulin therapy at baseline. Alirocumab dose was increased per protocol from 75 to 150&#x02009;mg Q2W at Week 12 if Week 8 LDL&#x02010;C was &#x02265;70&#x02009;mg/dL (1.8&#x02009;mmol/L) in 20% and 18% of those with or without DM, respectively.</p><table-wrap id="dom12909-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics, clinical characteristics and medical history in patients with or without diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) (randomized population)</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="2" id="dom12909-ent-0002" align="center" valign="bottom" rowspan="1">Patients with DM<xref ref-type="fn" rid="dom12909-note-0003">a</xref> (n&#x02009;=&#x02009;225)</th><th colspan="2" id="dom12909-ent-0003" align="center" valign="bottom" rowspan="1">Patients without DM (n&#x02009;=&#x02009;495)</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12909-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1">Alirocumab (n&#x02009;=&#x02009;148)</th><th id="dom12909-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">Ezetimibe (n&#x02009;=&#x02009;77)</th><th id="dom12909-ent-0006" align="left" valign="bottom" rowspan="1" colspan="1">Alirocumab (n&#x02009;=&#x02009;331)</th><th id="dom12909-ent-0007" align="left" valign="bottom" rowspan="1" colspan="1">Ezetimibe (n&#x02009;=&#x02009;164)</th></tr></thead><tbody valign="top"><tr><td id="dom12909-ent-0008" align="left" valign="top" rowspan="1" colspan="1">Age, years, mean (SD)</td><td id="dom12909-ent-0009" align="left" valign="top" rowspan="1" colspan="1">62.8 (9.1)</td><td id="dom12909-ent-0010" align="left" valign="top" rowspan="1" colspan="1">63.2 (8.8)</td><td id="dom12909-ent-0011" align="left" valign="top" rowspan="1" colspan="1">61.2 (9.5)</td><td id="dom12909-ent-0012" align="left" valign="top" rowspan="1" colspan="1">60.4 (9.3)</td></tr><tr><td id="dom12909-ent-0013" align="left" valign="top" rowspan="1" colspan="1">Male, % (n)</td><td id="dom12909-ent-0014" align="left" valign="top" rowspan="1" colspan="1">69.6 (103)</td><td id="dom12909-ent-0015" align="left" valign="top" rowspan="1" colspan="1">63.6 (49)</td><td id="dom12909-ent-0016" align="left" valign="top" rowspan="1" colspan="1">77.6 (257)</td><td id="dom12909-ent-0017" align="left" valign="top" rowspan="1" colspan="1">73.8 (121)</td></tr><tr><td id="dom12909-ent-0018" align="left" valign="top" rowspan="1" colspan="1">Race, white, % (n)</td><td id="dom12909-ent-0019" align="left" valign="top" rowspan="1" colspan="1">82.4 (122)</td><td id="dom12909-ent-0020" align="left" valign="top" rowspan="1" colspan="1">81.8 (63)</td><td id="dom12909-ent-0021" align="left" valign="top" rowspan="1" colspan="1">85.2 (282)</td><td id="dom12909-ent-0022" align="left" valign="top" rowspan="1" colspan="1">87.2 (143)</td></tr><tr><td id="dom12909-ent-0023" align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td id="dom12909-ent-0024" align="left" valign="top" rowspan="1" colspan="1">31.6 (5.9)</td><td id="dom12909-ent-0025" align="left" valign="top" rowspan="1" colspan="1">32.5 (5.2)</td><td id="dom12909-ent-0026" align="left" valign="top" rowspan="1" colspan="1">29.3 (5.0)</td><td id="dom12909-ent-0027" align="left" valign="top" rowspan="1" colspan="1">29.2 (4.7)</td></tr><tr><td id="dom12909-ent-0028" align="left" valign="top" rowspan="1" colspan="1">ASCVD, % (n)</td><td id="dom12909-ent-0029" align="left" valign="top" rowspan="1" colspan="1">89.2 (132)</td><td id="dom12909-ent-0030" align="left" valign="top" rowspan="1" colspan="1">79.2 (61)</td><td id="dom12909-ent-0031" align="left" valign="top" rowspan="1" colspan="1">99.4 (329)</td><td id="dom12909-ent-0032" align="left" valign="top" rowspan="1" colspan="1">99.4 (163)</td></tr><tr><td style="padding-left:10%" id="dom12909-ent-0033" align="left" valign="top" rowspan="1" colspan="1">CHD<xref ref-type="fn" rid="dom12909-note-0004">b</xref>
</td><td id="dom12909-ent-0034" align="left" valign="top" rowspan="1" colspan="1">82.4 (122)</td><td id="dom12909-ent-0035" align="left" valign="top" rowspan="1" colspan="1">72.7 (56)</td><td id="dom12909-ent-0036" align="left" valign="top" rowspan="1" colspan="1">95.2 (315)</td><td id="dom12909-ent-0037" align="left" valign="top" rowspan="1" colspan="1">95.1 (156)</td></tr><tr><td style="padding-left:15%" id="dom12909-ent-0038" align="left" valign="top" rowspan="1" colspan="1">ACS</td><td id="dom12909-ent-0039" align="left" valign="top" rowspan="1" colspan="1">58.1 (86)</td><td id="dom12909-ent-0040" align="left" valign="top" rowspan="1" colspan="1">51.9 (40)</td><td id="dom12909-ent-0041" align="left" valign="top" rowspan="1" colspan="1">74.3 (246)</td><td id="dom12909-ent-0042" align="left" valign="top" rowspan="1" colspan="1">76.8 (126)</td></tr><tr><td style="padding-left:15%" id="dom12909-ent-0043" align="left" valign="top" rowspan="1" colspan="1">Coronary revascularization procedure</td><td id="dom12909-ent-0044" align="left" valign="top" rowspan="1" colspan="1">56.8 (84)</td><td id="dom12909-ent-0045" align="left" valign="top" rowspan="1" colspan="1">54.5 (42)</td><td id="dom12909-ent-0046" align="left" valign="top" rowspan="1" colspan="1">74.3 (246)</td><td id="dom12909-ent-0047" align="left" valign="top" rowspan="1" colspan="1">75.0 (123)</td></tr><tr><td style="padding-left:15%" id="dom12909-ent-0048" align="left" valign="top" rowspan="1" colspan="1">Other clinically significant CHD</td><td id="dom12909-ent-0049" align="left" valign="top" rowspan="1" colspan="1">34.5 (51)</td><td id="dom12909-ent-0050" align="left" valign="top" rowspan="1" colspan="1">33.8 (26)</td><td id="dom12909-ent-0051" align="left" valign="top" rowspan="1" colspan="1">41.7 (138)</td><td id="dom12909-ent-0052" align="left" valign="top" rowspan="1" colspan="1">34.8 (57)</td></tr><tr><td style="padding-left:10%" id="dom12909-ent-0053" align="left" valign="top" rowspan="1" colspan="1">PAD</td><td id="dom12909-ent-0054" align="left" valign="top" rowspan="1" colspan="1">8.8 (13)</td><td id="dom12909-ent-0055" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0056" align="left" valign="top" rowspan="1" colspan="1">3.3 (11)</td><td id="dom12909-ent-0057" align="left" valign="top" rowspan="1" colspan="1">4.3 (7)</td></tr><tr><td style="padding-left:10%" id="dom12909-ent-0058" align="left" valign="top" rowspan="1" colspan="1">Ischaemic stroke</td><td id="dom12909-ent-0059" align="left" valign="top" rowspan="1" colspan="1">10.8 (16)</td><td id="dom12909-ent-0060" align="left" valign="top" rowspan="1" colspan="1">7.8 (6)</td><td id="dom12909-ent-0061" align="left" valign="top" rowspan="1" colspan="1">7.3 (24)</td><td id="dom12909-ent-0062" align="left" valign="top" rowspan="1" colspan="1">8.5 (14)</td></tr><tr><td id="dom12909-ent-0063" align="left" valign="top" rowspan="1" colspan="1">DM and &#x02265;2 additional risk factors<xref ref-type="fn" rid="dom12909-note-0005">c</xref>, % (n)</td><td id="dom12909-ent-0064" align="left" valign="top" rowspan="1" colspan="1">40.5 (60)</td><td id="dom12909-ent-0065" align="left" valign="top" rowspan="1" colspan="1">40.3 (31)</td><td id="dom12909-ent-0066" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0067" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td id="dom12909-ent-0068" align="left" valign="top" rowspan="1" colspan="1">Mean baseline HbA1c, % (SD)</td><td id="dom12909-ent-0069" align="left" valign="top" rowspan="1" colspan="1">6.8 (0.8)</td><td id="dom12909-ent-0070" align="left" valign="top" rowspan="1" colspan="1">6.8 (0.8)</td><td id="dom12909-ent-0071" align="left" valign="top" rowspan="1" colspan="1">5.7 (0.4)</td><td id="dom12909-ent-0072" align="left" valign="top" rowspan="1" colspan="1">5.7 (0.4)</td></tr><tr><td id="dom12909-ent-0073" align="left" valign="top" rowspan="1" colspan="1">Mean baseline FG, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0074" align="left" valign="top" rowspan="1" colspan="1">134.1 (37.3)</td><td id="dom12909-ent-0075" align="left" valign="top" rowspan="1" colspan="1">132.0 (39.8)</td><td id="dom12909-ent-0076" align="left" valign="top" rowspan="1" colspan="1">104.0 (14.8)</td><td id="dom12909-ent-0077" align="left" valign="top" rowspan="1" colspan="1">103.6 (15.3)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0078" align="left" valign="top" rowspan="1" colspan="1">[7.44 (2.07)]</td><td id="dom12909-ent-0079" align="left" valign="top" rowspan="1" colspan="1">[7.33 (2.21)]</td><td id="dom12909-ent-0080" align="left" valign="top" rowspan="1" colspan="1">[5.77 (0.82)]</td><td id="dom12909-ent-0081" align="left" valign="top" rowspan="1" colspan="1">[5.75 (0.85)]</td></tr><tr><td id="dom12909-ent-0082" align="left" valign="top" rowspan="1" colspan="1">Mean duration of DM, years (SD)</td><td id="dom12909-ent-0083" align="left" valign="top" rowspan="1" colspan="1">9.5 (9.2)</td><td id="dom12909-ent-0084" align="left" valign="top" rowspan="1" colspan="1">9.5 (9.4)</td><td id="dom12909-ent-0085" align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td id="dom12909-ent-0086" align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="5" id="dom12909-ent-0087" align="left" valign="top" rowspan="1">
<bold>Baseline lipids</bold>
</td></tr><tr><td id="dom12909-ent-0088" align="left" valign="top" rowspan="1" colspan="1">Calculated LDL&#x02010;C, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0089" align="left" valign="top" rowspan="1" colspan="1">108.2 (33.7)</td><td id="dom12909-ent-0090" align="left" valign="top" rowspan="1" colspan="1">99.3 (30.4)</td><td id="dom12909-ent-0091" align="left" valign="top" rowspan="1" colspan="1">108.7 (37.7)</td><td id="dom12909-ent-0092" align="left" valign="top" rowspan="1" colspan="1">107.2 (35.6)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0093" align="left" valign="top" rowspan="1" colspan="1">[2.8 (0.9)]</td><td id="dom12909-ent-0094" align="left" valign="top" rowspan="1" colspan="1">[2.6 (0.8)]</td><td id="dom12909-ent-0095" align="left" valign="top" rowspan="1" colspan="1">[2.8 (1.0)]</td><td id="dom12909-ent-0096" align="left" valign="top" rowspan="1" colspan="1">[2.8 (0.9)]</td></tr><tr><td id="dom12909-ent-0097" align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;HDL&#x02010;C, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0098" align="left" valign="top" rowspan="1" colspan="1">142.6 (41.3)</td><td id="dom12909-ent-0099" align="left" valign="top" rowspan="1" colspan="1">131.3 (31.7)</td><td id="dom12909-ent-0100" align="left" valign="top" rowspan="1" colspan="1">137.6 (40.0)</td><td id="dom12909-ent-0101" align="left" valign="top" rowspan="1" colspan="1">139.3 (43.7)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0102" align="left" valign="top" rowspan="1" colspan="1">[3.7 (1.1)]</td><td id="dom12909-ent-0103" align="left" valign="top" rowspan="1" colspan="1">[3.4 (0.8)]</td><td id="dom12909-ent-0104" align="left" valign="top" rowspan="1" colspan="1">[3.6 (1.0)]</td><td id="dom12909-ent-0105" align="left" valign="top" rowspan="1" colspan="1">[3.6 (1.1)]</td></tr><tr><td id="dom12909-ent-0106" align="left" valign="top" rowspan="1" colspan="1">Total cholesterol, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0107" align="left" valign="top" rowspan="1" colspan="1">186.2 (41.5)</td><td id="dom12909-ent-0108" align="left" valign="top" rowspan="1" colspan="1">174.2 (32.4)</td><td id="dom12909-ent-0109" align="left" valign="top" rowspan="1" colspan="1">186.6 (41.2)</td><td id="dom12909-ent-0110" align="left" valign="top" rowspan="1" colspan="1">188.5 (44.9)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0111" align="left" valign="top" rowspan="1" colspan="1">[4.8 (1.1)]</td><td id="dom12909-ent-0112" align="left" valign="top" rowspan="1" colspan="1">[4.5 (0.8)]</td><td id="dom12909-ent-0113" align="left" valign="top" rowspan="1" colspan="1">[4.8 (1.1)]</td><td id="dom12909-ent-0114" align="left" valign="top" rowspan="1" colspan="1">[4.9 (1.2)]</td></tr><tr><td id="dom12909-ent-0115" align="left" valign="top" rowspan="1" colspan="1">Apo B, mg/dL, mean (SD)</td><td id="dom12909-ent-0116" align="left" valign="top" rowspan="1" colspan="1">98.2 (23.8)</td><td id="dom12909-ent-0117" align="left" valign="top" rowspan="1" colspan="1">90.6 (19.0)</td><td id="dom12909-ent-0118" align="left" valign="top" rowspan="1" colspan="1">92.6 (22.7)</td><td id="dom12909-ent-0119" align="left" valign="top" rowspan="1" colspan="1">94.9 (24.8)</td></tr><tr><td id="dom12909-ent-0120" align="left" valign="top" rowspan="1" colspan="1">Apo&#x02010;A1, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0121" align="left" valign="top" rowspan="1" colspan="1">135.5 (21.8)</td><td id="dom12909-ent-0122" align="left" valign="top" rowspan="1" colspan="1">133.3 (23.4)</td><td id="dom12909-ent-0123" align="left" valign="top" rowspan="1" colspan="1">143.0 (24.0)</td><td id="dom12909-ent-0124" align="left" valign="top" rowspan="1" colspan="1">143.3 (25.8)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0125" align="left" valign="top" rowspan="1" colspan="1">[1.4 (0.2)]</td><td id="dom12909-ent-0126" align="left" valign="top" rowspan="1" colspan="1">[1.3 (0.2)]</td><td id="dom12909-ent-0127" align="left" valign="top" rowspan="1" colspan="1">[1.4 (0.2)]</td><td id="dom12909-ent-0128" align="left" valign="top" rowspan="1" colspan="1">[1.4 (0.3)]</td></tr><tr><td id="dom12909-ent-0129" align="left" valign="top" rowspan="1" colspan="1">Lp(a), mg/dL, median (Q1:Q3)</td><td id="dom12909-ent-0130" align="left" valign="top" rowspan="1" colspan="1">28.0 (8.0:68.5)</td><td id="dom12909-ent-0131" align="left" valign="top" rowspan="1" colspan="1">19.0 (6.0:43.0)</td><td id="dom12909-ent-0132" align="left" valign="top" rowspan="1" colspan="1">26.0 (8.0:70.0)</td><td id="dom12909-ent-0133" align="left" valign="top" rowspan="1" colspan="1">27.5 (10.0:66.5)</td></tr><tr><td id="dom12909-ent-0134" align="left" valign="top" rowspan="1" colspan="1">TG, mg/dL [mmol/L], median (Q1:Q3)</td><td id="dom12909-ent-0135" align="left" valign="top" rowspan="1" colspan="1">154.0 (109.0:220.0)</td><td id="dom12909-ent-0136" align="left" valign="top" rowspan="1" colspan="1">145.0 (123.0:199.0)</td><td id="dom12909-ent-0137" align="left" valign="top" rowspan="1" colspan="1">129.0 (93.0:172.0)</td><td id="dom12909-ent-0138" align="left" valign="top" rowspan="1" colspan="1">135.0 (100.5:198.0)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0139" align="left" valign="top" rowspan="1" colspan="1">[1.7 (1.2:2.5)]</td><td id="dom12909-ent-0140" align="left" valign="top" rowspan="1" colspan="1">[1.6 (1.4:2.2)]</td><td id="dom12909-ent-0141" align="left" valign="top" rowspan="1" colspan="1">[1.5 (1.1:1.9)]</td><td id="dom12909-ent-0142" align="left" valign="top" rowspan="1" colspan="1">[1.5 (1.1:2.2)]</td></tr><tr><td id="dom12909-ent-0143" align="left" valign="top" rowspan="1" colspan="1">HDL&#x02010;C, mg/dL [mmol/L], mean (SD)</td><td id="dom12909-ent-0144" align="left" valign="top" rowspan="1" colspan="1">43.6 (11.3)</td><td id="dom12909-ent-0145" align="left" valign="top" rowspan="1" colspan="1">42.9 (10.9)</td><td id="dom12909-ent-0146" align="left" valign="top" rowspan="1" colspan="1">49.0 (13.9)</td><td id="dom12909-ent-0147" align="left" valign="top" rowspan="1" colspan="1">49.1 (14.2)</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td id="dom12909-ent-0148" align="left" valign="top" rowspan="1" colspan="1">[1.1 (0.3)]</td><td id="dom12909-ent-0149" align="left" valign="top" rowspan="1" colspan="1">[1.1 (0.3)]</td><td id="dom12909-ent-0150" align="left" valign="top" rowspan="1" colspan="1">[1.3 (0.4)]</td><td id="dom12909-ent-0151" align="left" valign="top" rowspan="1" colspan="1">[1.3 (0.4)]</td></tr><tr><td id="dom12909-ent-0152" align="left" valign="top" rowspan="1" colspan="1">Taking high&#x02010;intensity statin therapy, % (n)</td><td id="dom12909-ent-0153" align="left" valign="top" rowspan="1" colspan="1">61.5 (91)</td><td id="dom12909-ent-0154" align="left" valign="top" rowspan="1" colspan="1">61.0 (47)</td><td id="dom12909-ent-0155" align="left" valign="top" rowspan="1" colspan="1">68.9 (228)</td><td id="dom12909-ent-0156" align="left" valign="top" rowspan="1" colspan="1">68.9 (113)</td></tr><tr><td id="dom12909-ent-0157" align="left" valign="top" rowspan="1" colspan="1">Any LMT other than statins, % (n)</td><td id="dom12909-ent-0158" align="left" valign="top" rowspan="1" colspan="1">6.1 (9)</td><td id="dom12909-ent-0159" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0160" align="left" valign="top" rowspan="1" colspan="1">6.3 (21)</td><td id="dom12909-ent-0161" align="left" valign="top" rowspan="1" colspan="1">6.7 (11)</td></tr><tr><td id="dom12909-ent-0162" align="left" valign="top" rowspan="1" colspan="1">Antidiabetic drug, % (n)</td><td id="dom12909-ent-0163" align="left" valign="top" rowspan="1" colspan="1">85.1 (126)</td><td id="dom12909-ent-0164" align="left" valign="top" rowspan="1" colspan="1">81.8 (63)</td><td id="dom12909-ent-0165" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0166" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td id="dom12909-ent-0167" align="left" valign="top" rowspan="1" colspan="1">Insulin, % (n)</td><td id="dom12909-ent-0168" align="left" valign="top" rowspan="1" colspan="1">22.3 (33)</td><td id="dom12909-ent-0169" align="left" valign="top" rowspan="1" colspan="1">16.9 (13)</td><td id="dom12909-ent-0170" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0171" align="left" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="dom12909-note-0002"><p>Abbreviations: <styled-content style="fixed-case">ACS</styled-content>, acute coronary syndrome; <styled-content style="fixed-case">A</styled-content>po, apolipoprotein; <styled-content style="fixed-case">ASCVD</styled-content>, atherosclerotic cardiovascular disease; <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">CHD</styled-content>, coronary heart disease; <styled-content style="fixed-case">FG</styled-content>, fasting glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">HDL&#x02010;C</styled-content>, high&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">LDL&#x02010;C</styled-content>, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">L</styled-content>p(a), lipoprotein (a); <styled-content style="fixed-case">MI</styled-content>, myocardial infarction; <styled-content style="fixed-case">PAD</styled-content>, peripheral artery disease; <styled-content style="fixed-case">SD</styled-content>, standard deviation; <styled-content style="fixed-case">TG</styled-content>, triglyceride.</p></fn><fn id="dom12909-note-0003"><label>a</label><p>Includes 2 patients with type 1 <styled-content style="fixed-case">DM</styled-content> in alirocumab arm.</p></fn><fn id="dom12909-note-0004"><label>b</label><p>Includes acute <styled-content style="fixed-case">MI</styled-content>, silent <styled-content style="fixed-case">MI</styled-content>, unstable angina, coronary revascularization procedure or other clinically significant <styled-content style="fixed-case">CHD</styled-content>.</p></fn><fn id="dom12909-note-0005"><label>c</label><p>Risk factors included hypertension; ankle&#x02010;brachial index of &#x02264;0.90; microalbuminuria, macroalbuminuria or a urinary dipstick result of &#x0003e;2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature <styled-content style="fixed-case">CHD</styled-content>.</p></fn></table-wrap-foot></table-wrap><sec id="dom12909-sec-0011"><label>3.1</label><title>Efficacy</title><p id="dom12909-para-0016">At Week 24, LDL&#x02010;C levels were reduced from baseline by 49.1% and 51.2% in alirocumab&#x02010;treated patients with or without DM, respectively, vs 18.4% and 21.8% in ezetimibe groups, respectively (<italic>P</italic>&#x02009;=&#x02009;.8052 for treatment by DM interaction; Figure <xref rid="dom12909-fig-0001" ref-type="fig">1</xref>A). A similar beneficial effect of alirocumab vs ezetimibe was also evident at the 12&#x02010;week assessment in both groups, with or without DM (Figure <xref rid="dom12909-fig-0001" ref-type="fig">1</xref>A). Moreover, LDL&#x02010;C reductions with alirocumab treatment were maintained over 104&#x02009;weeks in those with or without DM (Figure <xref rid="dom12909-fig-0001" ref-type="fig">1</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="dom12909-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean percentage change in calculated low&#x02010;density lipoprotein cholesterol (<styled-content style="fixed-case">LDL&#x02010;C</styled-content>) levels by diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) status. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">LDL&#x02010;C</styled-content> subgroup analysis at <styled-content style="fixed-case">W</styled-content>eeks 12 and 24 (<styled-content style="fixed-case">ITT</styled-content> analysis). <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">LDL&#x02010;C</styled-content> subgroup analysis over time (on&#x02010;treatment analysis)<sup>&#x02020;</sup>. <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">LDL&#x02010;C</styled-content> subgroup analysis over time (<styled-content style="fixed-case">ITT</styled-content>). <sup>&#x02020;</sup>On&#x02010;treatment includes all lipid data throughout the duration of study, collected while the patients were still receiving study treatment. <styled-content style="fixed-case">ITT</styled-content>, intent&#x02010;to&#x02010;treat (includes all lipid data regardless of adherence to treatment); <styled-content style="fixed-case">LS</styled-content>, least&#x02010;squares; <styled-content style="fixed-case">SE</styled-content>, standard error</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-989-g001"/></fig><p id="dom12909-para-0017">At Week 12, 80% of patients with DM and 82% of patients without DM were able to achieve LDL&#x02010;C levels &#x02264;70&#x02009;mg/dL (1.8&#x02009;mmol/L) on alirocumab 75&#x02009;mg Q2W (ie, without requiring dose increase to 150&#x02009;mg Q2W). At Week 24, LDL&#x02010;C target levels &#x02264;70&#x02009;mg/dL (1.8&#x02009;mmol/L) were achieved by 77.9% of alirocumab&#x02010;treated patients with DM and 77.3% of those without DM, compared with 50.1% and 45.1%, respectively, of ezetimibe&#x02010;treated patients. Treatment with alirocumab was associated with beneficial effects on non&#x02010;HDL&#x02010;C, Apo B, Lp(a) and HDL&#x02010;C levels, and a similar effect with ezetimibe on TG levels at 24&#x02009;weeks (Figure <xref rid="dom12909-fig-0002" ref-type="fig">2</xref>A&#x02010;E). All <italic>P</italic>&#x02010;values for interaction, comparing effect of alirocumab vs ezetimibe in patients with or without DM on LDL&#x02010;C and other lipid changes, were non&#x02010;significant (Figures <xref rid="dom12909-fig-0001" ref-type="fig">1</xref> and <xref rid="dom12909-fig-0002" ref-type="fig">2</xref>). Mean percentage changes in non&#x02010;HDL&#x02010;C, total cholesterol, ApoB, Apo&#x02010;A1, Lp(a), TGs and HDL&#x02010;C were broadly maintained over 104&#x02009;weeks for patients with or without DM, in both the ITT and on&#x02010;treatment analyses (Figures <xref rid="dom12909-supitem-0001" ref-type="supplementary-material">S2</xref> and <xref rid="dom12909-supitem-0001" ref-type="supplementary-material">S3</xref>, respectively).</p><fig fig-type="Figure" xml:lang="en" id="dom12909-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean percentage change in non&#x02010;high&#x02010;density lipoprotein cholesterol (non&#x02010;<styled-content style="fixed-case">HDL&#x02010;C</styled-content>), apolipoprotein (<styled-content style="fixed-case">A</styled-content>po) <styled-content style="fixed-case">B</styled-content>, lipoprotein(a) (<styled-content style="fixed-case">L</styled-content>p[a]), triglycerides (<styled-content style="fixed-case">TG</styled-content>) and <styled-content style="fixed-case">HDL&#x02010;C</styled-content> from baseline to <styled-content style="fixed-case">W</styled-content>eek 24 according to diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) status (<styled-content style="fixed-case">ITT</styled-content> analysis). <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">N</styled-content>on&#x02010;<styled-content style="fixed-case">HDL&#x02010;C</styled-content>. Interaction <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02010;value for treatment effect with vs without <styled-content style="fixed-case">DM</styled-content>, <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;=&#x02009;.4004. <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">A</styled-content>po <styled-content style="fixed-case">B</styled-content>. Interaction <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02010;value for treatment effect with vs without <styled-content style="fixed-case">DM</styled-content>, <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;=&#x02009;.5016. <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">L</styled-content>p(a). Interaction <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02010;value for treatment effect with vs without <styled-content style="fixed-case">DM</styled-content>, <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;=&#x02009;.5593. <styled-content style="fixed-case">D</styled-content>, <styled-content style="fixed-case">TGs</styled-content>. Interaction <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02010;value for treatment effect with vs without <styled-content style="fixed-case">DM</styled-content>, <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;=&#x02009;.3432. <styled-content style="fixed-case">E</styled-content>, <styled-content style="fixed-case">HDL&#x02010;C</styled-content>. Interaction <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02010;value for treatment effect with vs without <styled-content style="fixed-case">DM</styled-content>, <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;=&#x02009;.6232. <styled-content style="fixed-case">LS</styled-content>, least squares; <styled-content style="fixed-case">SE</styled-content>, standard error</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-19-989-g002"/></fig><p id="dom12909-para-0018">Overall, the mean rate of adherence to treatment (ie, percentage of days that patients received treatment per planned dosing schedule) was high, and was similar in patients with or without DM. Of patients treated with alirocumab, 97.3% with DM and 98.2% without DM were adherent to the SC injection regimen. In the ezetimibe control arm, 100.0% of patients with DM and 98.8% of patients without DM were adherent to placebo injections for alirocumab. Adherence to ezetimbe/placebo capsules was similarly high: in the alirocumab arm, 93.1% of patients with DM and 97.6% of patients without DM received capsules per planned dosing schedule; in the ezetimibe arm, 100.0% of patients with DM and 97.5% of patients without DM were adherent to the planned dosing schedule.</p></sec><sec id="dom12909-sec-0012"><label>3.2</label><title>Safety</title><p id="dom12909-para-0019">Median FG and HbA1c over the 104&#x02009;weeks of treatment were similar between treatment groups (Figure <xref rid="dom12909-fig-0003" ref-type="fig">3</xref>). Overall occurrence of treatment&#x02010;emergent AEs (TEAEs) up to 104&#x02009;weeks was similar between patients, with or without DM, and between treatment groups (Table <xref rid="dom12909-tbl-0002" ref-type="table-wrap">2</xref>); the percentage of patients who experienced at least 1 TEAE ranged from 80.5% to 82.9%. Deaths were reported for 6 (out of 479; 1.3%) patients in the alirocumab group (2 with and 4 without DM) and 6 patients (out of 241; 2.5%) in the ezetimibe group (1 with and 5 without DM). Serious AEs were experienced by 26.4% and 26.0% of patients with DM and 25.7% and 24.4% of patients without DM, treated with alirocumab and ezetimibe, respectively. TEAEs leading to discontinuation occurred in 10.1% and 9.1% of patients with DM and 8.8% and 7.3% of patients without DM, in the alirocumab and ezetimibe groups, respectively.</p><fig fig-type="Figure" xml:lang="en" id="dom12909-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Median glycated hemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) and fasting glucose (<styled-content style="fixed-case">FG</styled-content>) over 104&#x02009;weeks of treatment. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">HbA1c</styled-content>. <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">FG</styled-content>
</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-19-989-g003"/></fig><table-wrap id="dom12909-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Safety analysis up to 104&#x02009;weeks</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" id="dom12909-ent-0172" valign="bottom" colspan="1">% (n) of patients</th><th colspan="2" align="center" id="dom12909-ent-0173" valign="bottom" rowspan="1">Patients with DM (n&#x02009;=&#x02009;225)</th><th colspan="2" align="center" id="dom12909-ent-0174" valign="bottom" rowspan="1">Patients without DM (n&#x02009;=&#x02009;495)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12909-ent-0175" valign="bottom" rowspan="1" colspan="1">Alirocumab (n&#x02009;=&#x02009;148)</th><th align="left" id="dom12909-ent-0176" valign="bottom" rowspan="1" colspan="1">Ezetimibe (n&#x02009;=&#x02009;77)</th><th align="left" id="dom12909-ent-0177" valign="bottom" rowspan="1" colspan="1">Alirocumab (n&#x02009;=&#x02009;331)</th><th align="left" id="dom12909-ent-0178" valign="bottom" rowspan="1" colspan="1">Ezetimibe (n&#x02009;=&#x02009;164)</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12909-ent-0179" valign="top" rowspan="1" colspan="1">Any TEAE</td><td id="dom12909-ent-0180" align="left" valign="top" rowspan="1" colspan="1">81.1 (120)</td><td id="dom12909-ent-0181" align="left" valign="top" rowspan="1" colspan="1">80.5 (62)</td><td id="dom12909-ent-0182" align="left" valign="top" rowspan="1" colspan="1">81.9 (271)</td><td id="dom12909-ent-0183" align="left" valign="top" rowspan="1" colspan="1">82.9 (136)</td></tr><tr><td align="left" id="dom12909-ent-0184" valign="top" rowspan="1" colspan="1">Treatment&#x02010;emergent SAE</td><td id="dom12909-ent-0185" align="left" valign="top" rowspan="1" colspan="1">26.4 (39)</td><td id="dom12909-ent-0186" align="left" valign="top" rowspan="1" colspan="1">26.0 (20)</td><td id="dom12909-ent-0187" align="left" valign="top" rowspan="1" colspan="1">25.7 (85)</td><td id="dom12909-ent-0188" align="left" valign="top" rowspan="1" colspan="1">24.4 (40)</td></tr><tr><td align="left" id="dom12909-ent-0189" valign="top" rowspan="1" colspan="1">TEAEs leading to permanent discontinuation of study treatment</td><td id="dom12909-ent-0190" align="left" valign="top" rowspan="1" colspan="1">10.1 (15)</td><td id="dom12909-ent-0191" align="left" valign="top" rowspan="1" colspan="1">9.1 (7)</td><td id="dom12909-ent-0192" align="left" valign="top" rowspan="1" colspan="1">8.8 (29)</td><td id="dom12909-ent-0193" align="left" valign="top" rowspan="1" colspan="1">7.3 (12)</td></tr><tr><td align="left" id="dom12909-ent-0194" valign="top" rowspan="1" colspan="1">TEAEs leading to death</td><td id="dom12909-ent-0195" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0196" align="left" valign="top" rowspan="1" colspan="1">1.3 (1)</td><td id="dom12909-ent-0197" align="left" valign="top" rowspan="1" colspan="1">1.2 (4)</td><td id="dom12909-ent-0198" align="left" valign="top" rowspan="1" colspan="1">3.0 (5)</td></tr><tr><td colspan="5" align="left" id="dom12909-ent-0199" valign="top" rowspan="1">TEAEs occurring in &#x02265;5% of patients</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0200" valign="top" rowspan="1" colspan="1">Hypertension</td><td id="dom12909-ent-0201" align="left" valign="top" rowspan="1" colspan="1">8.1 (12)</td><td id="dom12909-ent-0202" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0203" align="left" valign="top" rowspan="1" colspan="1">6.3 (21)</td><td id="dom12909-ent-0204" align="left" valign="top" rowspan="1" colspan="1">5.5 (9)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0205" valign="top" rowspan="1" colspan="1">Upper respiratory tract infection</td><td id="dom12909-ent-0206" align="left" valign="top" rowspan="1" colspan="1">6.1 (9)</td><td id="dom12909-ent-0207" align="left" valign="top" rowspan="1" colspan="1">9.1 (7)</td><td id="dom12909-ent-0208" align="left" valign="top" rowspan="1" colspan="1">10.0 (33)</td><td id="dom12909-ent-0209" align="left" valign="top" rowspan="1" colspan="1">6.1 (10)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0210" valign="top" rowspan="1" colspan="1">Influenza</td><td id="dom12909-ent-0211" align="left" valign="top" rowspan="1" colspan="1">5.4 (8)</td><td id="dom12909-ent-0212" align="left" valign="top" rowspan="1" colspan="1">9.1 (7)</td><td id="dom12909-ent-0213" align="left" valign="top" rowspan="1" colspan="1">4.2 (14)</td><td id="dom12909-ent-0214" align="left" valign="top" rowspan="1" colspan="1">5.5 (9)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0215" valign="top" rowspan="1" colspan="1">Non&#x02010;cardiac chest pain</td><td id="dom12909-ent-0216" align="left" valign="top" rowspan="1" colspan="1">5.4 (8)</td><td id="dom12909-ent-0217" align="left" valign="top" rowspan="1" colspan="1">3.9 (3)</td><td id="dom12909-ent-0218" align="left" valign="top" rowspan="1" colspan="1">2.4 (8)</td><td id="dom12909-ent-0219" align="left" valign="top" rowspan="1" colspan="1">3.0 (5)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0220" valign="top" rowspan="1" colspan="1">Dizziness</td><td id="dom12909-ent-0221" align="left" valign="top" rowspan="1" colspan="1">4.7 (7)</td><td id="dom12909-ent-0222" align="left" valign="top" rowspan="1" colspan="1">5.2 (4)</td><td id="dom12909-ent-0223" align="left" valign="top" rowspan="1" colspan="1">6.9 (23)</td><td id="dom12909-ent-0224" align="left" valign="top" rowspan="1" colspan="1">8.5 (14)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0225" valign="top" rowspan="1" colspan="1">Headache</td><td id="dom12909-ent-0226" align="left" valign="top" rowspan="1" colspan="1">4.7 (7)</td><td id="dom12909-ent-0227" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0228" align="left" valign="top" rowspan="1" colspan="1">6.9 (23)</td><td id="dom12909-ent-0229" align="left" valign="top" rowspan="1" colspan="1">4.9 (8)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0230" valign="top" rowspan="1" colspan="1">Arthralgia</td><td id="dom12909-ent-0231" align="left" valign="top" rowspan="1" colspan="1">4.1 (6)</td><td id="dom12909-ent-0232" align="left" valign="top" rowspan="1" colspan="1">5.2 (4)</td><td id="dom12909-ent-0233" align="left" valign="top" rowspan="1" colspan="1">5.7 (19)</td><td id="dom12909-ent-0234" align="left" valign="top" rowspan="1" colspan="1">3.7 (6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0235" valign="top" rowspan="1" colspan="1">Bronchitis</td><td id="dom12909-ent-0236" align="left" valign="top" rowspan="1" colspan="1">4.1 (6)</td><td id="dom12909-ent-0237" align="left" valign="top" rowspan="1" colspan="1">9.1 (7)</td><td id="dom12909-ent-0238" align="left" valign="top" rowspan="1" colspan="1">3.6 (12)</td><td id="dom12909-ent-0239" align="left" valign="top" rowspan="1" colspan="1">3.0 (5)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0240" valign="top" rowspan="1" colspan="1">Fall</td><td id="dom12909-ent-0241" align="left" valign="top" rowspan="1" colspan="1">4.1 (6)</td><td id="dom12909-ent-0242" align="left" valign="top" rowspan="1" colspan="1">5.2 (4)</td><td id="dom12909-ent-0243" align="left" valign="top" rowspan="1" colspan="1">2.7 (9)</td><td id="dom12909-ent-0244" align="left" valign="top" rowspan="1" colspan="1">0.6 (1)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0245" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td><td id="dom12909-ent-0246" align="left" valign="top" rowspan="1" colspan="1">3.4 (5)</td><td id="dom12909-ent-0247" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0248" align="left" valign="top" rowspan="1" colspan="1">5.4 (18)</td><td id="dom12909-ent-0249" align="left" valign="top" rowspan="1" colspan="1">6.1 (10)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0250" valign="top" rowspan="1" colspan="1">Back pain</td><td id="dom12909-ent-0251" align="left" valign="top" rowspan="1" colspan="1">3.4 (5)</td><td id="dom12909-ent-0252" align="left" valign="top" rowspan="1" colspan="1">7.8 (6)</td><td id="dom12909-ent-0253" align="left" valign="top" rowspan="1" colspan="1">4.5 (15)</td><td id="dom12909-ent-0254" align="left" valign="top" rowspan="1" colspan="1">2.4 (4)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0255" valign="top" rowspan="1" colspan="1">Osteoarthritis</td><td id="dom12909-ent-0256" align="left" valign="top" rowspan="1" colspan="1">2.7 (4)</td><td id="dom12909-ent-0257" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0258" align="left" valign="top" rowspan="1" colspan="1">2.7 (9)</td><td id="dom12909-ent-0259" align="left" valign="top" rowspan="1" colspan="1">1.8 (3)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0260" valign="top" rowspan="1" colspan="1">Constipation</td><td id="dom12909-ent-0261" align="left" valign="top" rowspan="1" colspan="1">2.7 (4)</td><td id="dom12909-ent-0262" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0263" align="left" valign="top" rowspan="1" colspan="1">2.4 (8)</td><td id="dom12909-ent-0264" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0265" valign="top" rowspan="1" colspan="1">Myalgia</td><td id="dom12909-ent-0266" align="left" valign="top" rowspan="1" colspan="1">2.0 (3)</td><td id="dom12909-ent-0267" align="left" valign="top" rowspan="1" colspan="1">3.9 (3)</td><td id="dom12909-ent-0268" align="left" valign="top" rowspan="1" colspan="1">6.6 (22)</td><td id="dom12909-ent-0269" align="left" valign="top" rowspan="1" colspan="1">6.1 (10)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0270" valign="top" rowspan="1" colspan="1">Cough</td><td id="dom12909-ent-0271" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0272" align="left" valign="top" rowspan="1" colspan="1">5.2 (4)</td><td id="dom12909-ent-0273" align="left" valign="top" rowspan="1" colspan="1">3.6 (12)</td><td id="dom12909-ent-0274" align="left" valign="top" rowspan="1" colspan="1">3.7 (6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0275" valign="top" rowspan="1" colspan="1">Sinusitis</td><td id="dom12909-ent-0276" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0277" align="left" valign="top" rowspan="1" colspan="1">6.5 (5)</td><td id="dom12909-ent-0278" align="left" valign="top" rowspan="1" colspan="1">2.1 (7)</td><td id="dom12909-ent-0279" align="left" valign="top" rowspan="1" colspan="1">2.4 (4)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0280" valign="top" rowspan="1" colspan="1">Anxiety</td><td id="dom12909-ent-0281" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0282" align="left" valign="top" rowspan="1" colspan="1">5.2 (4)</td><td id="dom12909-ent-0283" align="left" valign="top" rowspan="1" colspan="1">1.5 (5)</td><td id="dom12909-ent-0284" align="left" valign="top" rowspan="1" colspan="1">1.2 (2)</td></tr><tr><td align="left" id="dom12909-ent-0285" valign="top" rowspan="1" colspan="1">Adjudicated treatment&#x02010;emergent cardiovascular events</td><td id="dom12909-ent-0286" align="left" valign="top" rowspan="1" colspan="1">8.8 (13)</td><td id="dom12909-ent-0287" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0288" align="left" valign="top" rowspan="1" colspan="1">5.4 (18)</td><td id="dom12909-ent-0289" align="left" valign="top" rowspan="1" colspan="1">6.7 (11)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0290" valign="top" rowspan="1" colspan="1">Non&#x02010;fatal myocardial infarction</td><td id="dom12909-ent-0291" align="left" valign="top" rowspan="1" colspan="1">3.4 (5)</td><td id="dom12909-ent-0292" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0293" align="left" valign="top" rowspan="1" colspan="1">3.3 (11)</td><td id="dom12909-ent-0294" align="left" valign="top" rowspan="1" colspan="1">1.8 (3)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0295" valign="top" rowspan="1" colspan="1">Fatal and non&#x02010;fatal ischaemic stroke (including stroke not otherwise specified)</td><td id="dom12909-ent-0296" align="left" valign="top" rowspan="1" colspan="1">0.7 (1)</td><td id="dom12909-ent-0297" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0298" align="left" valign="top" rowspan="1" colspan="1">0.3 (1)</td><td id="dom12909-ent-0299" align="left" valign="top" rowspan="1" colspan="1">0.6 (1)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0300" valign="top" rowspan="1" colspan="1">Unstable angina requiring hospitalization</td><td id="dom12909-ent-0301" align="left" valign="top" rowspan="1" colspan="1">0.7 (1)</td><td id="dom12909-ent-0302" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0303" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0304" align="left" valign="top" rowspan="1" colspan="1">0.6 (1)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0305" valign="top" rowspan="1" colspan="1">Congestive heart failure requiring hospitalization</td><td id="dom12909-ent-0306" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0307" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0308" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0309" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0310" valign="top" rowspan="1" colspan="1">Ischaemia driven coronary revascularization procedure</td><td id="dom12909-ent-0311" align="left" valign="top" rowspan="1" colspan="1">5.4 (8)</td><td id="dom12909-ent-0312" align="left" valign="top" rowspan="1" colspan="1">1.3 (1)</td><td id="dom12909-ent-0313" align="left" valign="top" rowspan="1" colspan="1">3.9 (13)</td><td id="dom12909-ent-0314" align="left" valign="top" rowspan="1" colspan="1">3.7 (6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12909-ent-0315" valign="top" rowspan="1" colspan="1">Adjudicated cardiovascular deaths on study<xref ref-type="fn" rid="dom12909-note-0007">a</xref>
</td><td id="dom12909-ent-0316" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0317" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12909-ent-0318" align="left" valign="top" rowspan="1" colspan="1">0.9 (3)</td><td id="dom12909-ent-0319" align="left" valign="top" rowspan="1" colspan="1">1.2 (2)</td></tr><tr><td align="left" id="dom12909-ent-0320" valign="top" rowspan="1" colspan="1">Any neurocognitive disorders TEAE</td><td id="dom12909-ent-0321" align="left" valign="top" rowspan="1" colspan="1">1.4 (2)</td><td id="dom12909-ent-0322" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0323" align="left" valign="top" rowspan="1" colspan="1">1.2 (4)</td><td id="dom12909-ent-0324" align="left" valign="top" rowspan="1" colspan="1">1.8 (3)</td></tr><tr><td align="left" id="dom12909-ent-0325" valign="top" rowspan="1" colspan="1">DM or diabetic complications TEAE</td><td id="dom12909-ent-0326" align="left" valign="top" rowspan="1" colspan="1">11.5 (17)</td><td id="dom12909-ent-0327" align="left" valign="top" rowspan="1" colspan="1">13.0 (10)</td><td id="dom12909-ent-0328" align="left" valign="top" rowspan="1" colspan="1">5.4 (18)</td><td id="dom12909-ent-0329" align="left" valign="top" rowspan="1" colspan="1">5.5 (9)</td></tr><tr><td align="left" id="dom12909-ent-0330" valign="top" rowspan="1" colspan="1">Injection&#x02010;site reaction (HLT)</td><td id="dom12909-ent-0331" align="left" valign="top" rowspan="1" colspan="1">0.7 (1)</td><td id="dom12909-ent-0332" align="left" valign="top" rowspan="1" colspan="1">2.6 (2)</td><td id="dom12909-ent-0333" align="left" valign="top" rowspan="1" colspan="1">3.6 (12)</td><td id="dom12909-ent-0334" align="left" valign="top" rowspan="1" colspan="1">0.6 (1)</td></tr></tbody></table><table-wrap-foot><fn id="dom12909-note-0006"><p>Abbreviations: <styled-content style="fixed-case">DM</styled-content>, diabetes mellitus; <styled-content style="fixed-case">HLT</styled-content>, high&#x02010;level term; <styled-content style="fixed-case">SAE</styled-content>, serious adverse event; <styled-content style="fixed-case">TEAE</styled-content>, treatment&#x02010;emergent adverse event.</p></fn><fn id="dom12909-note-0007"><label>a</label><p>Includes all deaths that occurred after initiation of treatment up to the last protocol visit of the patient.</p></fn></table-wrap-foot></table-wrap><p id="dom12909-para-0020">Treatment&#x02010;emergent cardiovascular events occurred in 8.8% and 2.6% of patients with DM and 5.4% and 6.7% of patients without DM, in the alirocumab and ezetimibe groups, respectively. There were few neurocognitive events in any group, with events occurring in 2 (1.4%) alirocumab patients and 2 (2.6%) ezetimibe patients with DM, and in 4 (1.2%) alirocumab patients and 3 (1.8%) ezetimibe patients without DM (Table <xref rid="dom12909-tbl-0002" ref-type="table-wrap">2</xref>). Injection site reactions (Medical Dictionary for Regulatory Activities High&#x02010;Level Term) occurred in 1 (0.7%) alirocumab patient and 2 (2.6%) ezetimibe patients with DM and in 12 (3.6%) alirocumab patients and 1 (0.6%) ezetimibe patient without DM, respectively.</p></sec></sec><sec id="dom12909-sec-0013"><label>4</label><title>DISCUSSION</title><p id="dom12909-para-0021">COMBO II was an ezetimibe&#x02010;controlled, double&#x02010;blind randomized trial that assessed the efficacy and safety of alirocumab vs ezetimibe in high cardiovascular risk patients receiving background maximally tolerated statin over 104&#x02009;weeks. Approximately one third of patients in the alirocumab (n&#x02009;=&#x02009;148; 31%) and ezetimibe (n&#x02009;=&#x02009;77; 32%) groups had DM at baseline. Results from this sub&#x02010;analysis indicate that the long&#x02010;term efficacy and safety of alirocumab in those with DM is similar to that in those without DM in patients with inadequately controlled LDL&#x02010;C. LDL&#x02010;C reductions at Week 24 with alirocumab (49.1%&#x02010;51.2% from baseline) were significantly greater than those with ezetimibe (18.4%&#x02010;21.8% from baseline) in this study. These reductions were consistent in patients with or without DM and were maintained to Week 104. Furthermore, results of this sub&#x02010;analysis demonstrate that alirocumab treatment does not affect measures of glycaemia; median FG and HbA1c remained similar in patients with or without DM, and were consistent with those observed in patients receiving ezetimibe. Moreover, in 80% of patients with DM and 82% of those without DM, 75&#x02009;mg alirocumab Q2W was sufficient to achieve risk&#x02010;based LDL&#x02010;C targets. Alirocumab was generally well tolerated and the occurrence of AEs was similar regardless of DM status. Injection site reactions occurred more frequently in the alirocumab arm, but did not occur more frequently in those with DM who were treated with alirocumab. In fact, the rate of injection site reactions with alirocumab was lower in those with DM (1 patient, 0.7%) vs those without DM (12 patients, 3.6%), potentially related to the fact that DM patients were more accustomed to receiving injectable therapies (22% of patients in the alirocumab group were receiving insulin) and/or to performing self&#x02010;monitoring of blood glucose. This pattern was not seen in the ezetimibe groups; however, the number of ezetimibe&#x02010;treated patients who received placebo injections and reported injection&#x02010;site reactions was low (3 patients overall).</p><p id="dom12909-para-0022">A possible limitation of this analysis is that, at randomization, patients were stratified according to history of myocardial infarction or ischaemic stroke, intensity of statin treatment and geographic region, to maintain a balance at baseline in factors that might influence outcome, but not DM status.<xref rid="dom12909-bib-0008" ref-type="ref">8</xref> Nevertheless, with the DM and non&#x02010;DM cohorts, treatment groups were balanced with regard to patient demographics and lipid profile at baseline.</p><p id="dom12909-para-0023">Findings from this subanalysis of the COMBO II study are in agreement with subanalyses from other ODYSSEY studies, showing no differences in efficacy between patients with or without DM.<xref rid="dom12909-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12909-bib-0010" ref-type="ref">10</xref> Furthermore, a pooled analysis of 10 ODYSSEY trials (including the COMBO II study) did not reveal an increase in new&#x02010;onset diabetes or adverse changes in glycaemic parameters with alirocumab treatment.<xref rid="dom12909-bib-0011" ref-type="ref">11</xref> A recently published study of the effects of the PCSK9 inhibitor evolocumab in patients with DM also found consistent reductions in atherogenic lipoproteins that were similar in patients with or without DM over the 12&#x02009;weeks of treatment.<xref rid="dom12909-bib-0012" ref-type="ref">12</xref> Our study, which assessed the effect of alirocumab for up to 104&#x02009;weeks, indicates that the impact of alirocumab on lipid parameters is maintained over the long term in patients with or without DM.</p><p id="dom12909-para-0024">To conclude, in the longest completed randomized double&#x02010;blind controlled trial evaluating a PCSK9 inhibitor to date, alirocumab provided clinically relevant greater reductions in LDL&#x02010;C in patients with DM than those obtained with ezetimibe, with a similar safety profile. These reductions were maintained over the 104&#x02010;week duration of the study and were comparable in patients without DM. In addition, treatment with alirocumab enabled more patients, with or without DM, to achieve LDL&#x02010;C goals as compared with ezetimibe, with a 75&#x02009;mg Q2W alirocumab dose sufficient for the majority of patients to attain their risk&#x02010;based LDL&#x02010;C goal. Further specific studies of the efficacy and safety of alirocumab in patients with DM are currently ongoing (NCT02642159, NCT02585778) and treatment with alirocumab for potential reduction of cardiovascular events is being evaluated in the large ongoing ODYSSEY OUTCOMES study (NCT01663402) which includes a substantial proportion of patients with DM.<xref rid="dom12909-bib-0013" ref-type="ref">13</xref>
</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12909-supitem-0001"><caption><p id="dom12909-para-0001">
<bold>Figure S1.</bold>
<styled-content style="fixed-case">COMBO II</styled-content> study design.</p><p id="dom12909-para-0002">
<bold>Figure S2.</bold> Mean percentage change in non&#x02010;high&#x02010;density lipoprotein cholesterol (non&#x02010;<styled-content style="fixed-case">HDL&#x02010;C</styled-content>), total cholesterol, apolipoprotein (<styled-content style="fixed-case">A</styled-content>po) <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">A</styled-content>po&#x02010;<styled-content style="fixed-case">A1</styled-content>, lipoprotein(a) (<styled-content style="fixed-case">L</styled-content>p[a]), triglyceride (<styled-content style="fixed-case">TG</styled-content>), and <styled-content style="fixed-case">HDL&#x02010;C</styled-content> from baseline at <styled-content style="fixed-case">W</styled-content>eek 24 according to diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) status (<styled-content style="fixed-case">ITT</styled-content> analysis).</p><p id="dom12909-para-0003">
<bold>Figure S3.</bold> Mean percentage change in non&#x02010;high&#x02010;density lipoprotein cholesterol (non&#x02010;<styled-content style="fixed-case">HDL&#x02010;C</styled-content>), total cholesterol, apolipoprotein (<styled-content style="fixed-case">A</styled-content>po) <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">A</styled-content>po&#x02010;<styled-content style="fixed-case">A1</styled-content>, lipoprotein(a) (<styled-content style="fixed-case">L</styled-content>p[a]), triglyceride (<styled-content style="fixed-case">TG</styled-content>), and <styled-content style="fixed-case">HDL&#x02010;C</styled-content> from baseline at <styled-content style="fixed-case">W</styled-content>eek 24 according to diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) status (<styled-content style="fixed-case">O</styled-content>n&#x02010;treatment analysis).<sup>&#x02020;</sup>
</p></caption><media xlink:href="DOM-19-989-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12909-sec-0014"><title>ACKNOWLEDGEMENTS</title><p id="dom12909-para-0025">The authors would like to thank the study patients and investigators, and the following persons from the sponsors for their contributions to data collection and analysis, assistance with statistical analysis, or critical review of the manuscript: Jay Edelberg, Eva&#x02010;Lynne Greene, Michael Howard, Carol Hudson, Veronica Lee, Rita Samuel and Bill Sasiela. Medical writing support was provided by Talya Underwood of Prime Medica Ltd, Knutsford, Cheshire, UK, supported by Sanofi and Regeneron Pharmaceuticals.</p><sec id="dom12909-sec-0015"><title>Conflict of interest</title><p id="dom12909-para-0026">L. A. L. has served on an advisory panel for Aegerion, Amgen, AstraZeneca, Eli Lilly, Merck, Regeneron and Sanofi; has received research support from Amgen, AstraZeneca, Eli Lilly, Medicine Company, Merck, Pfizer, Regeneron and Sanofi; and has served on speaker's bureaus for Amgen, AstraZeneca, Merck and Sanofi. J. L. Z. has served as a speaker for Abbott, Philips and Merck Sharp &#x00026; Dohme. M. B.&#x02010;B. and G. L. are employees of and stockholders in Sanofi. M. J. L. is an employee of and stockholder in Regeneron. C. P. C. has received personal fees from Sanofi and Regeneron during the conduct of the study; grants from Accumetrics, Arisaph, AstraZeneca, Boehringer&#x02010;Ingelheim and Janssen; personal fees from BMS, CSL Behring, Essentialis and Lipimedix; and grants and personal fees from GlaxoSmithKline, Merck and Takeda, outside the submitted work. Y. H. has received research grants, and consultant and speaker honoraria from Amarin, Amgen, AZ, BMS, BI, Eisai, Essperion, Grifolis, GSK Hamni, Intarcia, Janssen, Lexicon, Lilly, Merck, Novo Nordisk, Pfizer, Regeneron, Sanofi, Takeda and Vivus and is Immediate Past President of The American College of Endocrinology.</p></sec></ack><ref-list content-type="cited-references" id="dom12909-bibl-0001"><title>REFERENCES</title><ref id="dom12909-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12909-cit-0001">
<string-name>
<surname>Verges</surname>
<given-names>B</given-names>
</string-name>. <article-title>Pathophysiology of diabetic dyslipidaemia: where are we?</article-title>
<source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>:<fpage>886</fpage>&#x02010;<lpage>899</lpage>.<pub-id pub-id-type="pmid">25725623</pub-id></mixed-citation></ref><ref id="dom12909-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12909-cit-0002">
<string-name>
<surname>Stone</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>AH</given-names>
</string-name>, et al. <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>(<issue>suppl</issue>):<fpage>S1</fpage>&#x02010;<lpage>S45</lpage>.<pub-id pub-id-type="pmid">24222016</pub-id></mixed-citation></ref><ref id="dom12909-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12909-cit-0003">
<string-name>
<surname>Reiner</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Catapano</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>De Backer</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>1769</fpage>&#x02010;<lpage>1818</lpage>.<pub-id pub-id-type="pmid">21712404</pub-id></mixed-citation></ref><ref id="dom12909-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12909-cit-0004">
<collab collab-type="authors" id="dom12909-gp-0001">American Diabetes Association</collab>
. <article-title>8. Cardiovascular disease and risk management</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>(<issue>suppl</issue>):<fpage>S49</fpage>&#x02010;<lpage>S57</lpage>.<pub-id pub-id-type="pmid">25537708</pub-id></mixed-citation></ref><ref id="dom12909-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12909-cit-0005">
<string-name>
<surname>Bays</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>WV</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</string-name>, <collab collab-type="authors" id="dom12909-gp-0002">National Lipid Association</collab>
. <article-title>National Lipid Association annual summary of clinical lipidology 2015</article-title>. <source>J Clin Lipidol</source>. <year>2014</year>;<volume>8</volume>(<issue>suppl</issue>):<fpage>S1</fpage>&#x02010;<lpage>S36</lpage>.</mixed-citation></ref><ref id="dom12909-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12909-cit-0006">
<string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Farnier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Krempf</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Efficacy and safety of alirocumab in reducing lipids and cardiovascular events</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>1489</fpage>&#x02010;<lpage>1499</lpage>.<pub-id pub-id-type="pmid">25773378</pub-id></mixed-citation></ref><ref id="dom12909-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12909-cit-0007">
<string-name>
<surname>Farnier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gaudet</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Valcheva</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Minini</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cariou</surname>
<given-names>B</given-names>
</string-name>. <article-title>Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials</article-title>. <source>Int J Cardiol</source>. <year>2016</year>;<volume>223</volume>:<fpage>750</fpage>&#x02010;<lpage>757</lpage>.<pub-id pub-id-type="pmid">27573600</pub-id></mixed-citation></ref><ref id="dom12909-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12909-cit-0008">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Cariou</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Blom</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>1186</fpage>&#x02010;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">25687353</pub-id></mixed-citation></ref><ref id="dom12909-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12909-cit-0009">
<string-name>
<surname>Colhoun</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Farnier</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2014</year>;<volume>14</volume>:<fpage>121</fpage>.<pub-id pub-id-type="pmid">25240705</pub-id></mixed-citation></ref><ref id="dom12909-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12909-cit-0010">
<string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Langslet</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>2996</fpage>&#x02010;<lpage>3003</lpage>.<pub-id pub-id-type="pmid">26330422</pub-id></mixed-citation></ref><ref id="dom12909-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12909-cit-0011">
<string-name>
<surname>Colhoun</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, et al. <article-title>No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2981</fpage>&#x02010;<lpage>2989</lpage>.<pub-id pub-id-type="pmid">27460890</pub-id></mixed-citation></ref><ref id="dom12909-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12909-cit-0012">
<string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Preiss</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, et al. <article-title>Lipid&#x02010;lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta&#x02010;analysis of individual patient data</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2016</year>;<volume>4</volume>:<fpage>403</fpage>&#x02010;<lpage>410</lpage>.<pub-id pub-id-type="pmid">26868195</pub-id></mixed-citation></ref><ref id="dom12909-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12909-cit-0013">
<string-name>
<surname>Schwartz</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Bessac</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Berdan</surname>
<given-names>LG</given-names>
</string-name>, et al. <article-title>Effect of alirocumab, a monoclonal antibody to PCSK9, on long&#x02010;term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial</article-title>. <source>Am Heart J</source>. <year>2014</year>;<volume>168</volume>:<fpage>682</fpage>&#x02010;<lpage>689</lpage>.<pub-id pub-id-type="pmid">25440796</pub-id></mixed-citation></ref></ref-list></back></article>